MITF maintains genome stability in nonmelanocyte lineages
Molecular Oncology · 2026-11 · 20 (11) · 2839-2859
DOI: 10.1002/1878-0261.70273 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 10.06.2026. Verfasst von Drifa H Gudmundsdottir und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Laboratory, Faculty of Medicine, University of Iceland, Reykjavik, Iceland. Hauptthemen laut MEDLINE: Microphthalmia-Associated Transcription Factor, Genomic Instability, Cell Lineage. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Icelandic Cancer Society Research Fund, Rannís.
Abstract (Originalsprache)
Microphthalmia‐associated transcription factor (MITF) is crucial for development and survival of melanocytes and serves as a lineage‐specific oncogene that is amplified in 10–20% of melanomas. The role of MITF in pathways maintaining genome integrity, such as DNA replication, DNA repair, and mitosis has been extensively studied in melanocytes. In addition to its pro‐survival role in melanoma, recent studies have shown that MITF expression has important implications for cancer progression and treatment in other cancer types. Nevertheless, studies on the role of MITF in other tissues are scarce. Here, we show that depletion of MITF causes genome instability in nonmelanocytic cell lineages, which results in activation of P53, cell cycle arrest, and apoptosis. Moreover, we show that P53 activation in MITF‐depleted cells is dependent on LATS2, a kinase with an established role in the Hippo pathway. Finally, we show that LATS2 mediated upregulation of P53 is ATR‐dependent. Collectively, this study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage, which might contribute to the tumor suppressive function of MITF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Research Laboratory, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
- Biomedical Center, University of Iceland, Reykjavik, Iceland.
- Department of Molecular Oncology, University Hospital of Iceland, Reykjavik, Iceland.
- Department of Genetics and Molecular Medicine, University Hospital of Iceland, Reykjavik, Iceland.
- Biotech Research & Innovation Center, University of Copenhagen, Denmark.
ORCID-Profile: Drifa H Gudmundsdottir, Eirikur Steingrimsson, Stefan Sigurdsson
Förderung
- The Icelandic Cancer Society Research Fund
- Rannís
Zitieren
APA
Gudmundsdottir, D. H., de Lomana, A. L. G., Venkatesh, T. B., Kirty, K., Sigurdsson, S., Vidarsdottir, L., Dilshat, R., Sveinbjornsdottir, E., Ragnarsdottir, S., Magnusson, D. H., Bustos, M. R., Steingrimsson, E., Gudjonsson, T., & Sigurdsson, S. (2026). MITF maintains genome stability in nonmelanocyte lineages. Molecular Oncology, 20(11), 2839-2859. https://doi.org/10.1002/1878-0261.70273
Vancouver
Gudmundsdottir DH, de Lomana ALG, Venkatesh TB, Kirty K, Sigurdsson S, Vidarsdottir L, et al. MITF maintains genome stability in nonmelanocyte lineages. Molecular Oncology. 2026;20(11):2839-2859. doi:10.1002/1878-0261.70273
BibTeX
@article{Gudmundsdottir2026,
author = {Gudmundsdottir, Drifa H and de Lomana, Adrián López García and Venkatesh, Thejus B and Kirty, Kritika and Sigurdsson, Snaevar and Vidarsdottir, Linda and Dilshat, Ramile and Sveinbjornsdottir, Erla and Ragnarsdottir, Snaedis and Magnusson, Daniel H and Bustos, Maria R and Steingrimsson, Eirikur and Gudjonsson, Thorkell and Sigurdsson, Stefan},
title = {MITF maintains genome stability in nonmelanocyte lineages},
journal = {Molecular Oncology},
year = {2026},
volume = {20},
number = {11},
pages = {2839--2859},
doi = {10.1002/1878-0261.70273}
}
EUVIMED